Rhythm Pharmaceuticals, Inc.
RYTM
Rankning i aktier
#2937
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Aktiekurs
$89.83
Marknadsvärde
$6.18B
Förändring (1 dag)
1.81%
Förändring (1 år)
-20.07%
Land
US
Handel Rhythm Pharmaceuticals, Inc. (RYTM)
Kategori
Healthcare
P/S-tal för Rhythm Pharmaceuticals, Inc. (RYTM)
P/S-tal per October 2026 TTM: 24.79
Enligt Rhythm Pharmaceuticals, Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/S-talet (TTM) 24.79. I slutet av 2023 hade företaget ett P/S-tal på 34.24.
Historik för P/S-tal för Rhythm Pharmaceuticals, Inc. från 2012 till 2026
P/S-tal vid årets slut
| År | P/S-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 24.79 | -5.52% |
| 2024 | 26.24 | -23.37% |
| 2023 | 34.24 | -46.67% |
| 2022 | 64.21 | -59.09% |
| 2021 | 156.95 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
P/S-tal för liknande företag eller konkurrenter
| Företag | P/S-tal | Skillnad i P/S-tal | Land |
|---|---|---|---|
| 10.02 | -59.57% |
US
|
|
| 40.55 | 63.57% |
US
|
|
| 3.96 | -84.02% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -59.07% |
NL
|
